DEA moves to extend telehealth prescribing flexibilities after voluminous stakeholder feedback
The agency says it is reviewing a deluge of comments on its February proposed rulemaking ending telehealth prescriptions for certain controlled substances. Its unclear how far this new extension will last beyond the end of the PHE.
Powered by WPeMatico